Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
Read More >
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers